title: Endothelin receptor remodeling induces the portal venous hyper-response to endothelin-1 following endotoxin pretreatment.
abstract: The purpose of this study was to determine the changes in endothelin (ET) receptor subtype expression and their functional significance after endotoxin pretreatment. Rats were pretreated with lipopolysaccharide (LPS) or sterile saline (control). After 24 h, liver samples were homogenized and competitive receptor binding assays were performed. There was no significant difference in ET receptor binding affinity between the control and LPS groups. However, the receptor subtype density showed a significant increase in ET(B) receptors in LPS-treated rats, whereas the amount of ET(A) receptors was almost identical between the two groups. In control, almost all ET receptors (95%) were displaced by using combined ET(A) antagonist (BQ-610) and ET(B) agonist (IRL-1620) as competitors, whereas only 80% (P < 0.05 versus control) was displaced in LPS group, raising the possibility of novel type of ET receptor expression. An infusion of ET(B) agonist (Sarafotoxin 6c, S6c) through portal vein in isolated perfused livers produced the same pressure response in both LPS and control groups; however, the portal pressure increase in response to the ET-1, which binds all ET receptors, was significantly potentiated in LPS-treated rats compared to controls. We conclude that altered regulation of ET receptors, in particular, the appearance of ET binding capacity that is not displaced by ET(A) or ET(B) competitors, may explain the hyper-response of the portal venous system to ET-1 during endotoxemia.
authors.affiliation: Department of Biology, University of North Carolina, Charlotte 28223, USA.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: Rajiv
authors.initials: R
authors.lastname: Baveja
authors.forename: Nicole
authors.initials: N
authors.lastname: Kresge
authors.forename: Natalie
authors.initials: N
authors.lastname: Sonin
authors.forename: Kazuya
authors.initials: K
authors.lastname: Nakanishi
authors.forename: Jian X
authors.initials: JX
authors.lastname: Zhang
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Gitzelmann
authors.forename: Mark G
authors.initials: MG
authors.lastname: Clemens
mesh_terms: D000818:Animals; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000378:metabolism / Q000494:pharmacology*; D004731:Endotoxins / Q000494:pharmacology*; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology; D008099:Liver / Q000098:blood supply* / Q000187:drug effects*; D008297:Male; D017082:Portal Pressure / Q000187:drug effects; D011169:Portal Vein / Q000187:drug effects* / Q000503:physiopathology*; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D017466:Receptors, Endothelin / Q000819:agonists / Q000378:metabolism*; D013816:Thermodynamics
chemical_list: D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D004731:Endotoxins; D008070:Lipopolysaccharides; D017466:Receptors, Endothelin